Document Detail

Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
MedLine Citation:
PMID:  15911925     Owner:  NLM     Status:  MEDLINE    
Preclinical and clinical studies suggest that anthracycline-induced cardiotoxicity can be prevented by administering coenzyme Q10 during cancer chemotherapy that includes drugs such as doxorubicin and daunorubicin. Studies further suggest that coenzyme Q10 does not interfere with the antineoplastic action of anthracyclines and might even enhance their anticancer effects. Preventing cardiotoxicity might allow for escalation of the anthracycline dose, which would further enhance the anticancer effects. Based on clinical investigation, although limited, a cumulative dose of doxorubicin of up to 900 mg/m2, and possibly higher, can be administered safely during chemotherapy as long as coenzyme Q10 is administered concurrently. The etiology of the dose-limiting cardiomyopathy that is induced by anthracyclines can be explained by irreversible damage to heart cell mitochondria, which differ from mitochondria of other cells in that they possess a unique enzyme on the inner mitochondrial membrane. This enzyme reduces anthracyclines to their semiquinones, resulting in severe oxidative stress, disruption of mitochondrial energetics, and irreversible damage to mitochondrial DNA. Damage to mitochondrial DNA blocks the regenerative capability of the organelle and ultimately leads to apoptosis or necrosis of myocytes. Coenzyme Q10, an essential component of the electron transport system and a potent intracellular antioxidant, appears to prevent damage to the mitochondria of the heart, thus preventing the development of anthracycline-induced cardiomyopathy.
Kenneth A Conklin
Related Documents :
2308845 - Recombination via flanking direct repeats is a major cause of large-scale deletions of ...
9920795 - Antioxidant agent nimesulid and beta-blocker metoprolol do not exert protective effects...
12525865 - Live now--pay by ageing: high performance mitochondrial activity in youth and its age-r...
8513395 - The mitochondrial dna transfer rna(lys)a-->g(8344) mutation and the syndrome of myoclon...
12403775 - Deficient in dna methylation 1 (ddm1) defines a novel family of chromatin-remodeling fa...
21666255 - Single qdot-labeled glycosylase molecules use a wedge amino acid to probe for lesions w...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Integrative cancer therapies     Volume:  4     ISSN:  1534-7354     ISO Abbreviation:  Integr Cancer Ther     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-05-24     Completed Date:  2005-09-29     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  101128834     Medline TA:  Integr Cancer Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  110-30     Citation Subset:  IM    
Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1778, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anthracyclines / administration & dosage,  adverse effects*,  pharmacology
Antibiotics, Antineoplastic / administration & dosage,  adverse effects*,  pharmacology
Antioxidants / administration & dosage,  pharmacology*
Cardiomyopathies / chemically induced,  drug therapy,  prevention & control*
Dose-Response Relationship, Drug
Drug Therapy, Combination
Heart / drug effects
Heart Failure / prevention & control
Mitochondria, Heart / drug effects*
Neoplasms / drug therapy
Ubiquinone / administration & dosage,  analogs & derivatives*,  pharmacology
Reg. No./Substance:
0/Anthracyclines; 0/Antibiotics, Antineoplastic; 0/Antioxidants; 0/Coenzymes; 1339-63-5/Ubiquinone; 303-98-0/coenzyme Q10

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Leg ulcers are a diagnostic and therapeutic challenge.
Next Document:  Acupuncture: role in comprehensive cancer care--a primer for the oncologist and review of the litera...